Literature DB >> 11714904

Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning.

X Monnet1, B Ghaleh, P Colin, O P de Curzon, J F Giudicelli, A Berdeaux.   

Abstract

We investigated the effects of the selective bradycardic agent ivabradine, an I(f) channel inhibitor, on exercise-induced ischemia and resulting myocardial stunning. Seven dogs were chronically instrumented to measure left ventricular (LV) wall thickening (Wth), aortic pressure and coronary blood flow (CBFv) (Doppler). Circumflex coronary artery stenosis was set up to suppress the increase in CBFv during a 10 min treadmill exercise. During exercise under saline, LVWth in the ischemic zone was depressed (-70 +/- 4%) and a prolonged myocardial stunning was subsequently observed. Infusion of ivabradine started before exercise significantly reduced heart rate (HR) at rest (-22 +/- 7%), during exercise (-33 +/- 4%) and throughout the recovery period (-21 +/- 2%). By reducing HR during exercise, ivabradine simultaneously improved LVWth compared with saline (14 +/- 1% versus 7 +/- 1%, respectively) and subendocardial perfusion (microspheres). This anti-ischemic effect was subsequently responsible for a strong decrease in the intensity and severity of myocardial stunning. All these beneficial effects were abolished when HR reduction during exercise was suppressed by atrial pacing. Interestingly, when ivabradine infusion was started after exercise, LVWth was still significantly enhanced and myocardial stunning strongly attenuated. This direct effect of ivabradine on the stunned myocardium disappeared when HR reduction was suppressed by atrial pacing at rest. In conclusion, this study demonstrates that ivabradine exerts an anti-ischemic effect that is responsible for subsequent protection against myocardial stunning. Furthermore, administration of ivabradine after the ischemic insult still improves LVWth of the stunned myocardium.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714904

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

Review 1.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

Review 2.  Is heart rate a treatment target in heart failure?

Authors:  Jan-Christian Reil; Michael Böhm
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

3.  Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery.

Authors:  Domenico Vitale; Vincenzo De Santis; Fabio Guarracino; Andrea Fontana; Fabio Pellegrini; Luigi Tritapepe
Journal:  Clin Res Cardiol       Date:  2010-09-07       Impact factor: 5.460

4.  Effects of ivabradine on allograft function and exercise performance in heart transplant recipients with permanent sinus tachycardia.

Authors:  R Zhang; A Haverich; M Strüber; A Simon; M Pichlmaier; Christoph Bara
Journal:  Clin Res Cardiol       Date:  2008-07-21       Impact factor: 5.460

Review 5.  Heart rate, autonomic markers, and cardiac mortality.

Authors:  Richard L Verrier; Alex Tan
Journal:  Heart Rhythm       Date:  2009-09-01       Impact factor: 6.343

Review 6.  Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention.

Authors:  Cosmo Godino; Antonio Colombo; Alberto Margonato
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

Review 7.  Preclinical results with I(f) current inhibition by ivabradine.

Authors:  Alain Berdeaux
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Niflumic acid alters gating of HCN2 pacemaker channels by interaction with the outer region of S4 voltage sensing domains.

Authors:  Lan Cheng; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2009-02-13       Impact factor: 4.436

9.  Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction.

Authors:  Jan-Christian Reil; Mathias Hohl; Gert-Hinrich Reil; Henk L Granzier; Mario T Kratz; Andrey Kazakov; Peter Fries; Andreas Müller; Matthias Lenski; Florian Custodis; Stefan Gräber; Gerd Fröhlig; Paul Steendijk; Hans-Ruprecht Neuberger; Michael Böhm
Journal:  Eur Heart J       Date:  2012-07-24       Impact factor: 29.983

10.  I(f) channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities.

Authors:  Xiao-Jun Du; Xinheng Feng; Xiao-Ming Gao; Tze Ping Tan; Helen Kiriazis; Anthony M Dart
Journal:  Br J Pharmacol       Date:  2004-04-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.